Latest News and Press Releases

The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of...

REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at...

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of...

Alvotech (NASDAQ: ALVO) og samstarfsaðilar félagsins, Kashiv Biosciences og Advanz Pharma, kynntu í dag að jákvæð niðurstaða hefði náðst í klínískri rannsókn sem bar saman virkni AVT23, fyrirhugaðrar...

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines...

Mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hefur mælt með því að heimila markaðssetningu AVT06, sem er fyrirhuguð hliðstæða augnlyfsins Eylea (aflibercept), þróuð af Alvotech. Framkvæmdastjórn...

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and...

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að fyrirtækið afhent bréf til þátttakenda í lokuðu hlutafjárútboði sem fram fór þann 4. júní sl. Um 40 stofnanafjárfestar tóku þátt í útboðinu. Um 60%...

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...